A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Estrogen receptors (ERs) modulate gene transcription via estrogen response elements (EREs) and AP-1 sites.
• Selective estrogen receptor modulators (SERMs) like Raloxifene and Tamoxifen exhibit complex ER antagonism/agonism.
• Existing SERMs act as ER antagonists on EREs but can be agonists on AP-1 responsive genes.

Purpose of the Study:

• To develop a mutant selective analog of Raloxifene.
• To investigate the activity profile of novel ER antagonists.
• To characterize a new compound, DRL527, with a unique ERE/AP-1 activity.

Main Methods:

• Development of a mutant selective Raloxifene analog.
• Antagonist screening against wild-type ERα and ERβ.
• Assessment of ER/AP-1 response element activity.

Main Results:

• Discovery of DRL527, an antagonist of both wild-type ERα and ERβ.
• DRL527 functions as an antagonist of ERβ/AP-1 response.
• DRL527 represses basal AP-1 gene expression and antagonizes Raloxifene-stimulated AP-1 activity.

Conclusions:

• DRL527 exhibits a unique ERE/AP-1 activity profile, distinct from known SERMs.
• This compound represents a novel class of ER modulators.
• DRL527's unique profile may offer new therapeutic strategies for estrogen-mediated conditions.